50 closest statements
by meaning · ranked by similarity · 100 per pageMeaning search returns the 50 nearest statements, then applies your filters.
“Our mission is to leverage our unique insights into the chromatin regulatory system to pioneer the discovery, development and commercialization of a new class of therapies that transform the lives of patients suffering from a wide spectrum of diseases with high unmet need.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1187% match
“Our mission is to leverage our unique insights into finding and binding cryptic functional pockets on currently intractable human biology-validated protein targets to discover, develop and commercialize small molecule therapies that can transform the lives of patients suffering from devastating cancers and immune disorders.”In use 2021 – now·1 sighting·SEC Form S-1, filed 2021-06-2570% match
“Our mission is to discover and develop novel therapeutics to address significant medical needs.”In use 2007 – now·1 sighting·SEC Form 10-K, filed 2007-03-1970% match
“Our mission is to discover, develop and commercialize novel and transformative therapies that improve the lives of patients with serious diseases.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-02-2270% match
“Our mission is to offer an ecosystem of innovative discovery and translational research solutions that enable our customers to map the universe of biology and conduct scientific exploration that may lead to new therapies to improve the human condition.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-02-2870% match
“Our mission is to create disease-modifying neurogenetic medicines by identifying validated targets, advancing multiple therapeutic modalities, and delivering them to the right areas within the central nervous system.”In use 2025 – now·1 sighting·SEC Form 10-K, filed 2025-03-1170% match
“Our mission is to discover, develop and commercialize a new class of RNA editing therapies capable of improving the lives of patients with rare and highly prevalent diseases.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1269% match
“Our mission is to develop innovative, transformative therapies for patients with devastating diseases through the use of our novel chRDNA genome-editing technology.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0569% match
“Our mission is to become the leading company in precision genetic medicines by discovering, developing, manufacturing, and ultimately commercializing a new class of medicines through our proprietary base editing technology, with the goal of providing life-long cures to patients suffering from serious diseases.”In use 2020 – now·1 sighting·SEC Form 424B4, filed 2020-10-0169% match
“Our mission is to change the landscape of oncology drug discovery and enable the development of more effective therapies for the treatment of cancer.”In use 2025 – now·1 sighting·SEC Form S-1, filed 2025-07-1869% match
“Our mission is to leverage unique insights into protein motion to transform the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of small molecule therapies.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2669% match
“Our mission is to be the foremost biopharma company interrogating ecDNA biology to deliver transformative therapies that improve and extend the lives of patients with previously intractable oncogene amplified cancers.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0969% match
“Our mission is to enable the rapid development of innovative therapeutics by pushing the frontiers of drug discovery technologies.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0469% match
“Our mission is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of our patients.”In use 2019 – now·1 sighting·SEC Form 10-K, filed 2019-03-0769% match
“Our mission is to enable anyone and any company to use our integrated open-access drug discovery and development platform to discover and develop new therapeutic products to benefit patients worldwide.”In use 2015 – now·1 sighting·SEC Form 20-F, filed 2015-04-1569% match
“Our mission is to enable customers across the continuum of molecular research and clinical testing to unlock valuable insights faster, better and more efficiently - from the raw biological sample to the final interpreted results.”In use 2022 – now·1 sighting·SEC Form 20-F, filed 2022-03-1469% match
“Our mission is to develop products and services based on leading genomics technologies that improve outcomes and enable improved effectiveness, productivity and safety in the research efforts of drug discovery and development companies worldwide.”In use 2003 – now·1 sighting·SEC Form 10-K, filed 2003-03-1969% match
“Our mission is to develop next generation cell and gene therapeutics with the capacity to cure.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-0768% match
“Our mission is to target cancer and transform lives through the development of innovative cancer treatments.”In use 2005 – now·1 sighting·SEC Form 10-K, filed 2005-03-1668% match
“Our mission is to become a leading global, fully integrated biopharmaceutical company engaged in discovering, developing and commercializing both first- and best-in-class therapies to address global unmet medical needs primarily in hematological malignancies.”In use 2025 – now·1 sighting·SEC Form 424B4, filed 2025-01-2468% match
“Our mission is to discover and develop novel therapeutic drugs to treat diseases and disorders for which there are no adequate therapies or for which a new drug would represent a significant advancement over the current therapy.”In use 2003 – now·1 sighting·SEC Form 10-K, filed 2003-03-1468% match
“Our mission is to develop and commercialize first-in-class medicines based on novel targets to improve patients’ lives.”In use 2022 – now·1 sighting·SEC Form 20-F, filed 2022-03-2468% match
“Our mission is to transform cancer care through the smart design and development of targeted solutions based on a deep understanding of cancer pathways and biological markers.”In use 2019 – now·1 sighting·SEC Form 10-K, filed 2019-03-0668% match
“Our mission is to transform cancer treatment and prevention globally by driving technological innovation and accelerating the adoption of precision oncology medicine.”In use 2020 – now·1 sighting·SEC Form 424B4, filed 2020-06-2268% match
“Our mission is to create, develop, manufacture, and deliver cell and gene therapies to transform the lives of people impacted by life-threatening diseases.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-1868% match
“Our mission is to discover, develop and ultimately deliver medicines that are transformational for patients.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-2868% match
“Our mission is to be a leading global biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies that improve the lives of patients.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2668% match
“Our mission is to maximize the clinical and commercial potential of cabozantinib, and to position us for future growth through our discovery efforts and expansion of our development pipeline.”In use 2019 – now·1 sighting·SEC Form 10-K, filed 2019-02-2267% match
“Our mission is to deliver innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases.”In use 2022 – now·1 sighting·SEC Form 10-K, filed 2022-03-2467% match
“Our mission is to transform the lives of patients through the creation of novel gene control medicines by building a fully integrated, leading biopharmaceutical company.”In use 2017 – now·1 sighting·SEC Form 10-K, filed 2017-03-2067% match
“Our mission is to build the world’s leading endocrine company that pioneers new therapeutics to help patients better control their disease and improve their daily lives.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2667% match
“Our mission is to build a breakthrough oncology company creating neoantigen-based therapies that significantly improve the lives of patients.”In use 2018 – now·1 sighting·SEC Form 424B4, filed 2018-06-2867% match
“Our mission is to leverage an integrated and extensive genomics and transcriptomics discovery engine to identify antibodies targeted to newly discovered neoepitopes and to mobilize the human immune system of cancer patients to kill tumor cells and facilitate long-term remission.”In use 2017 – now·1 sighting·SEC Form 10-K, filed 2017-03-1567% match
“Our mission is to improve the lives of patients by developing novel therapeutics to treat some of the most devastating types of cancer.”In use 2026 – now·1 sighting·SEC Form 10-K/A, filed 2026-06-0267% match
“Our mission is to be the global leader and pioneer of this new treatment paradigm, integrating recombinant technology, gene therapy and cell therapy to address the challenges of targeting and delivering effective therapies, including to the brain for cancer and other central nervous system (“CNS”) indications.”In use 2026 – now·1 sighting·SEC Form S-1, filed 2026-08-2867% match
“Our mission is to imagine and pioneer new ways to decode the biology of the proteome to improve human health.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0267% match
“Our mission is to provide drug and product developers with superior scientific research, high-quality research models and innovative analytical instrumentation in order to bring revolutionary new drugs and products to market quickly and safely.”In use 2021 – now·1 sighting·SEC Form S-1, filed 2021-12-2367% match
“Our mission is to build a leading oncology company that creates novel and transformative treatments for a wide range of oncology indications for which there are significant unmet medical needs.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-0767% match
“Our mission is to build the leading coagulation company by discovering, developing, and commercializing innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases.”In use 2026 – now·1 sighting·SEC Form 424B4, filed 2026-05-0167% match
“Our mission is to translate the promise of gene editing into a broad class of differentiated, transformational medicines for previously untreatable diseases.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0967% match
“Our mission is to create differentiated, innovative products by applying our platform technologies to established or novel medicines.”In use 2008 – now·1 sighting·SEC Form 10-K, filed 2008-02-2967% match
“Our mission is to develop and commercialize therapies with the potential to transform the lives of patients and their families living with rare diseases.”In use 2022 – now·1 sighting·SEC Form 10-K, filed 2022-03-0167% match
“Our mission is to develop next-generation, potentially curative cell therapies for people with cancer.”In use 2025 – now·1 sighting·SEC Form 10-K, filed 2025-03-1267% match
“Our mission is to advance novel therapies, leveraging evidence-based innovation, with the potential to transform the lives of people suffering from serious, chronic conditions and unmet medical needs.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-09-2567% match
“Our mission is to commercialize innovative drug candidates with novel mechanisms of action as well as intellectual property generated from our research activities for neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease.”In use 2018 – now·1 sighting·SEC Form 10-K, filed 2018-07-1667% match
“Our mission is to create transformative gene-based medicines for serious human diseases.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-1267% match
“Our mission is to advance and grow a portfolio of innovative, early-stage oncology assets based on the latest scientific breakthroughs focused on overcoming immune resistance and expanding the addressable patient population.”In use 2023 – now·1 sighting·SEC Form 20-F, filed 2023-07-3167% match
“Our mission is to accelerate the discovery, development and global access to targeted radioligand therapies.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-03-2767% match
“Our mission is to identify, acquire, and accelerate the development and commercialization of medicines that we believe have the potential to offer clinically meaningful, differentiated benefits to patients.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-2867% match
“Our mission is to develop first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy, or DMD, and other rare disorders.”In use 2020 – now·1 sighting·SEC Form 10-K, filed 2020-03-2766% match
Showing 1–50 of 50